166 related articles for article (PubMed ID: 11133819)
1. Candidate mutator genes in mismatch repair-deficient thymic lymphomas: no evidence of mutations in the DNA polymerase delta gene.
Campbell MR; Thang TY; Jirik FR; Andrew SE
Carcinogenesis; 2000 Dec; 21(12):2281-5. PubMed ID: 11133819
[TBL] [Abstract][Full Text] [Related]
2. Thymic lymphomas arising in Msh2 deficient mice display a large increase in mutation frequency and an altered mutational spectrum.
Zhang S; Lloyd R; Bowden G; Glickman BW; de Boer JG
Mutat Res; 2002 Mar; 500(1-2):67-74. PubMed ID: 11890935
[TBL] [Abstract][Full Text] [Related]
3. Tumors arising in DNA mismatch repair-deficient mice show a wide variation in mutation frequency as assessed by a transgenic reporter gene.
Baross-Francis A; Milhausen MK; Andrew SE; Jevon G; Jirik FR
Carcinogenesis; 2000 Jun; 21(6):1259-62. PubMed ID: 10837019
[TBL] [Abstract][Full Text] [Related]
4. Tumors of DNA mismatch repair-deficient hosts exhibit dramatic increases in genomic instability.
Baross-Francis A; Andrew SE; Penney JE; Jirik FR
Proc Natl Acad Sci U S A; 1998 Jul; 95(15):8739-43. PubMed ID: 9671748
[TBL] [Abstract][Full Text] [Related]
5. MSH2-deficient murine lymphomas harbor insertion/deletion mutations in the transforming growth factor beta receptor type 2 gene and display low not high frequency microsatellite instability.
Lowsky R; Magliocco A; Ichinohasama R; Reitmair A; Scott S; Henry M; Kadin ME; DeCoteau JF
Blood; 2000 Mar; 95(5):1767-72. PubMed ID: 10688836
[TBL] [Abstract][Full Text] [Related]
6. Alterations in PMS2, MSH2 and MLH1 expression in human prostate cancer.
Chen Y; Wang J; Fraig MM; Henderson K; Bissada NK; Watson DK; Schweinfest CW
Int J Oncol; 2003 May; 22(5):1033-43. PubMed ID: 12684669
[TBL] [Abstract][Full Text] [Related]
7. Exonuclease 1 preferentially repairs mismatches generated by DNA polymerase α.
Liberti SE; Larrea AA; Kunkel TA
DNA Repair (Amst); 2013 Feb; 12(2):92-6. PubMed ID: 23245696
[TBL] [Abstract][Full Text] [Related]
8. Base transitions dominate the mutational spectrum of a transgenic reporter gene in MSH2 deficient mice.
Andrew SE; Reitmair AH; Fox J; Hsiao L; Francis A; McKinnon M; Mak TW; Jirik FR
Oncogene; 1997 Jul; 15(2):123-9. PubMed ID: 9244348
[TBL] [Abstract][Full Text] [Related]
9. Neurofibromatosis type 1 gene as a mutational target in a mismatch repair-deficient cell type.
Wang Q; Montmain G; Ruano E; Upadhyaya M; Dudley S; Liskay RM; Thibodeau SN; Puisieux A
Hum Genet; 2003 Feb; 112(2):117-23. PubMed ID: 12522551
[TBL] [Abstract][Full Text] [Related]
10. Transgenic expression of human MGMT blocks the hypersensitivity of PMS2-deficient mice to low dose MNU thymic lymphomagenesis.
Qin X; Zhou H; Liu L; Gerson SL
Carcinogenesis; 1999 Sep; 20(9):1667-73. PubMed ID: 10469609
[TBL] [Abstract][Full Text] [Related]
11. DNA mismatch repair deficiency stimulates N-ethyl-N-nitrosourea-induced mutagenesis and lymphomagenesis.
Claij N; van der Wal A; Dekker M; Jansen L; te Riele H
Cancer Res; 2003 May; 63(9):2062-6. PubMed ID: 12727820
[TBL] [Abstract][Full Text] [Related]
12. Reconstitution of
Bowen N; Kolodner RD
Proc Natl Acad Sci U S A; 2017 Apr; 114(14):3607-3612. PubMed ID: 28265089
[TBL] [Abstract][Full Text] [Related]
13. Cell lineage-specific effects associated with multiple deficiencies of tumor susceptibility genes in Msh2(-/-)Rb(+/-) mice.
Nikitin AY; Liu CY; Flesken-Nikitin A; Chen CF; Chen PL; Lee WH
Cancer Res; 2002 Sep; 62(18):5134-8. PubMed ID: 12234974
[TBL] [Abstract][Full Text] [Related]
14. A lack of DNA mismatch repair on an athymic murine background predisposes to hematologic malignancy.
Campbell MR; Nation PN; Andrew SE
Cancer Res; 2005 Apr; 65(7):2626-35. PubMed ID: 15805259
[TBL] [Abstract][Full Text] [Related]
15. Mutational specificity of mice defective in the MTH1 and/or the MSH2 genes.
Egashira A; Yamauchi K; Yoshiyama K; Kawate H; Katsuki M; Sekiguchi M; Sugimachi K; Maki H; Tsuzuki T
DNA Repair (Amst); 2002 Nov; 1(11):881-93. PubMed ID: 12531017
[TBL] [Abstract][Full Text] [Related]
16. Defects of the mismatch repair gene MSH2 are implicated in the development of murine and human lymphoblastic lymphomas and are associated with the aberrant expression of rhombotin-2 (Lmo-2) and Tal-1 (SCL).
Lowsky R; DeCoteau JF; Reitmair AH; Ichinohasama R; Dong WF; Xu Y; Mak TW; Kadin ME; Minden MD
Blood; 1997 Apr; 89(7):2276-82. PubMed ID: 9116269
[TBL] [Abstract][Full Text] [Related]
17. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer.
de Wind N; Dekker M; Berns A; Radman M; te Riele H
Cell; 1995 Jul; 82(2):321-30. PubMed ID: 7628020
[TBL] [Abstract][Full Text] [Related]
18. Two mismatch repair gene mutations found in a colon cancer patient--which one is pathogenic?
Kariola R; Otway R; Lönnqvist KE; Raevaara TE; Macrae F; Vos YJ; Kohonen-Corish M; Hofstra RM; Nyström-Lahti M
Hum Genet; 2003 Feb; 112(2):105-9. PubMed ID: 12522549
[TBL] [Abstract][Full Text] [Related]
19. Mutator phenotype in Msh2-deficient murine embryonic fibroblasts.
Reitmair AH; Risley R; Bristow RG; Wilson T; Ganesh A; Jang A; Peacock J; Benchimol S; Hill RP; Mak TW; Fishel R; Meuth M
Cancer Res; 1997 Sep; 57(17):3765-71. PubMed ID: 9288785
[TBL] [Abstract][Full Text] [Related]
20. Mutagenesis in PMS2- and MSH2-deficient mice indicates differential protection from transversions and frameshifts.
Andrew SE; Xu XS; Baross-Francis A; Narayanan L; Milhausen K; Liskay RM; Jirik FR; Glazer PM
Carcinogenesis; 2000 Jul; 21(7):1291-5. PubMed ID: 10874005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
